跳到正文
制药经理人· GxP知识岛·· 9 天前AI 评分71

FDA发布昭衍(苏州)新药研究中心483检查报告,5天检查列2项观察

FDA 483:昭衍(苏州)新药研究中心有限公司!

AI 导读

FDA于2026年5月15日向昭衍(苏州)新药研究中心有限公司(FEI 3012611386)签发483检查报告,2026年5月11日至15日的检查共列2项观察。

正文

近日,FDA发布了昭衍(苏州)新药研究中心有限公司(江苏省苏州市太仓市生物医药产业园昭溪路1号,FEI 3012611386)的483检查报告,检查5天,列2项观察。

两项观察的标题都很笼统:一项是“试验机构管理未能确保所有人员清楚理解其应履行的职能”,另一项是“试验机构的规模和构造不适合非临床研究的正常开展”。具体问题全在子项里:档案系统记63袋湿组织、实物只点到62袋;病理切片把背侧和腹侧的标签对调;试剂没标有效期;温湿度记录没用修正值;动物房地面不向地漏倾斜、PVC 地面起泡开裂,还有一道门的锁扣固定不住——非人灵长类能把门推开。

图1 FDA 483 原件第1页(FEI 3012611386,2026年5月15日签发)

Inspection Details

检查基本信息

Firm / 企业

JOINN Laboratories (Suzhou) Co., Ltd. 昭衍(苏州)新药研究中心有限公司

Address / 地址

No. 1 Zhaoxi Road, Biomedical Industrial Park, Taicang, Suzhou, Jiangsu, 215421 China(江苏省苏州市太仓市生物医药产业园昭溪路1号)

FEI Number / FEI 号

3012611386

Dates of Inspection / 检查日期

2026年5月11日–5月15日

Type Establishment Inspected / 受检设施类型

Non-clinical Laboratory(非临床实验室)

Issued To / 收件人

Sucai (nmi) Zhang,Test Facility Manager(试验机构负责人)

District Office / 地区办公室

10903 New Hampshire Avenue, Building 51, Silver Spring, MD 20993(电话 301-796-3150,传真 301-594-1204)

Issued / 签发

2026年5月15日 检查员:Julian C. Hanson;Andrew R. Wasko II(Biologist);Xinguang Li(Senior Pharmacokinetist);Lakecha N. Lewis

说明:原件为 FDA 统一格式表格,未逐条印出法规条款号。仅第1项观察的 d 目直接引用了 21 CFR 58.83;其余条款对应关系见文末译注①。

OBSERVATION 1

观察1:人员对职责的理解(编者对应 21 CFR 58.31(f))

Testing facility management failed to assure that all personnel clearly understood the functions they were to perform.

试验机构管理未能确保所有人员清楚理解其应履行的职能。

Specifically,

具体而言,

a. Section 4.3.1 of SOP ADM-027 Version 16, "Archive Administration," effective July 5, 2023, states, "The study number, archive date, specimen type, storage location, amount and other relevant information shall be documented in database (the Ziguang Archive management software)."

a. SOP ADM-027 第16版《档案管理》(2023年7月5日生效)第4.3.1条规定:“研究编号、归档日期、标本类型、存放位置、数量及其他相关信息,均应记录在数据库(紫光档案管理软件)中。”

For study (b)(4), the Ziguang archive management software entry listed 63 wet tissue bags on May 11, 2026; however, 62 wet tissue bags were physically verified as archived on shelves 52-1-7 and 51-3-7 in Building 8, room 8103.

研究 (b)(4) 在紫光档案管理软件中的记录显示,2026年5月11日为63袋湿组织;但实物核对时,仅在8号楼8103室的52-1-7和51-3-7货架上点到62袋。

b. Section 4.3.1 (Specimen Storage) of SOP ADM-027 Version 23.0, "Archive Administration," effective March 23, 2026, states, "When Document Management System (DMS) is adopted, the archive administrator shall enter the information such as the specific placement position and quantity of the samples."

b. SOP ADM-027 第23.0版《档案管理》(2026年3月23日生效)第4.3.1条(标本贮存)规定:“采用文件管理系统(DMS)时,档案管理员应录入样品的具体存放位置、数量等信息。”

Thirty-four trays of (b)(4) blocks (e.g. (b)(4)) were temporarily stored in the Building 27 document archives (room 27104) due to space limitations in the Building 27 specimen archives (room 27102), however, DMS was not updated to reflect this temporary storage location when observed on May 11, 2026.

三十四盘 (b)(4) 蜡块(如 (b)(4))因27号楼标本档案室(27102室)空间不足,暂存于27号楼文件档案室(27104室);2026年5月11日检查时,DMS 未更新以反映这一临时存放位置。

c. Section 4.2.5 of SOP PATH-020 Version 3, "Microtomy of (b)(4) Sections," effective February 2, 2023, states, "Verify the block code and record the block code on the glass slide (or verify the block code if the glass slide is printed with a block code)."

c. SOP PATH-020 第3版《(b)(4) 切片制作》(2023年2月2日生效)第4.2.5条规定:“核对蜡块编号,并将蜡块编号记录在载玻片上(若载玻片已印有蜡块编号,则核对蜡块编号)。”

For study (b)(4), upon comparing the (b)(4) blocks to the corresponding slides, the slide generated from (b)(4) block (b)(4) code 3 (brain section 3, dorsal) was erroneously labeled as (b)(4) code 3B (brain section 3, ventral), and the slide generated from (b)(4) block (b)(4) code 3B (brain section 3, ventral) was erroneously labeled as (b)(4) code 3 (brain section 3, dorsal).

研究 (b)(4) 中,将 (b)(4) 蜡块与对应切片比对后发现:由 (b)(4) 蜡块 (b)(4) 编号3(脑第3切片,背侧)制成的切片,被错误标为 (b)(4) 编号3B(脑第3切片,腹侧);由 (b)(4) 蜡块 (b)(4) 编号3B(脑第3切片,腹侧)制成的切片,被错误标为 (b)(4) 编号3(脑第3切片,背侧)。

d. 21 CFR 58.83 states, "All reagents and solutions in the laboratory areas shall be labeled to indicate identity, titer or concentration, storage requirements, and expiration date."

d. 21 CFR 58.83 规定:“实验区域内的所有试剂和溶液均应加贴标签,标明名称、滴度或浓度、贮存要求和有效期。”

Mobile phase for GLP study (b)(4) found in room 8232 was not labeled with an expiration date or storage conditions.

在8232室发现的一瓶 GLP 研究 (b)(4) 用流动相,未标注有效期或贮存条件。

e. Section 4.5.1.2 of SOP ADM-029 Version 15.0, "Use and Management of Equipment," effective April 2, 2026, states, "When using the following externally calibrated/verified equipment, their corrected values or error values should be introduced ***. Hygrometers used for monitoring environmental temperature and humidity (excluding EBI system monitoring probes)."

e. SOP ADM-029 第15.0版《设备使用与管理》(2026年4月2日生效)第4.5.1.2条规定:“使用下列经外部校准/确认的设备时,应引入其修正值或误差值***。用于监测环境温湿度的湿度计(不包括 EBI 系统监测探头)。”

The Room Temperature and Humidity Record (Form BA-041-F03) for Room 8237 recorded temperature and humidity readings twice daily without applying the corrected values from April 2, 2026, through May 12, 2026.

8237室的《室温与湿度记录》(表单 BA-041-F03)在2026年4月2日至5月12日期间每日两次记录温湿度读数,均未引入修正值。

OBSERVATION 2

观察2:设施规模与构造(编者对应 21 CFR 58.41)

The testing facility is not of suitable size and construction to facilitate the proper conduct of nonclinical laboratory studies.

试验机构的规模和构造,不适合非临床实验室研究的正常开展。

Specifically,

具体而言,

a. In Building 7, where reserve animals were being held, the floor in one area of animal room 7176 did not slope toward the drain. We observed discoloration and pooling liquid in one part of this area.

a. 在存放备用动物的7号楼,7176动物房其中一处地面未向地漏倾斜。我们在该区域的一部分看到变色和积液。

b. In Building 7, in the corridor near room 7178, we observed bubbling and cracking in the surface of the PVC floor.

b. 在7号楼7178室附近的走廊,我们看到 PVC 地面表层起泡、开裂。

c. In Building 5, near animal room 5264, the vertical locking mechanism for the door separating the silent area corridor would not stay in place. We observed non-human primates pushing this door open while undergoing observations.

c. 在5号楼5264动物房附近,分隔静音区走廊的那道门,其竖向锁定装置无法固定。我们观察到非人灵长类在观察过程中把这道门推开。

来源:制药经理人 · mp.weixin.qq.com

事件后续 · 1

查看事件全部